Department of Medicine, Cook County Health, Chicago, IL, USA.
Division of Cardiology, Cook County Health, Rush University Medical Center, Chicago, IL, USA.
Syst Rev. 2022 Jul 23;11(1):147. doi: 10.1186/s13643-022-02029-9.
The Measurement Tool to Assess systematic Reviews (AMSTAR) 2 is a critical appraisal tool for systematic reviews (SRs) and meta-analyses (MAs) of interventions. We aimed to perform the first AMSTAR 2-based quality assessment of heart failure-related studies.
Eleven high-impact journals were searched from 2009 to 2019. The included studies were assessed on the basis of 16 domains. Seven domains were deemed critical for high-quality studies. On the basis of the performance in these 16 domains with different weights, overall ratings were generated, and the quality was determined to be "high," "moderate," "low," or "critically low."
Eighty-one heart failure-related SRs with MAs were included. Overall, 79 studies were of "critically low quality" and two were of "low quality." These findings were attributed to insufficiency in the following critical domains: a priori protocols (compliance rate, 5%), complete list of exclusions with justification (5%), risk of bias assessment (69%), meta-analysis methodology (78%), and investigation of publication bias (60%).
The low ratings for these potential high-quality heart failure-related SRs and MAs challenge the discrimination capacity of AMSTAR 2. In addition to identifying certain areas of insufficiency, these findings indicate the need to justify or modify AMSTAR 2's rating rules.
评估系统评价的工具（AMSTAR 2）是干预措施的系统评价（SRs）和荟萃分析（MAs）的关键性评价工具。我们旨在对与心力衰竭相关的研究进行首次基于 AMSTAR 2 的质量评估。
从 2009 年到 2019 年，搜索了 11 种高影响力的期刊。根据 16 个领域对纳入的研究进行评估。有 7 个领域被认为是高质量研究的关键。根据这些 16 个领域的表现和不同的权重，生成了总体评分，并确定质量为“高”、“中”、“低”或“极低”。
共纳入 81 项与心力衰竭相关的 SR 与 MA。总体而言，有 79 项研究的质量为“极低”，有 2 项研究的质量为“低”。这些发现归因于以下关键领域的不足：预先设定的方案（符合率为 5%）、有充分理由的完整排除清单（5%）、偏倚风险评估（69%）、荟萃分析方法（78%）和对发表偏倚的调查（60%）。
这些潜在高质量的与心力衰竭相关的 SR 和 MA 的低评级挑战了 AMSTAR 2 的辨别能力。除了确定某些不足领域外，这些发现还表明需要对 AMSTAR 2 的评分规则进行论证或修改。
